文献速递技术与安全神经泌尿生殖PET

肿瘤诊疗一体化:放射科医生需要了解的内容

Theranostics in oncology: What radiologists want to know.
PubMed 文献 · Eur J Radiol · 2021-07-26

本文综述了放射性配体成像与治疗联合的诊疗一体化在肿瘤精准医疗中的应用。重点讨论了基于生长抑素受体高表达的神经内分泌肿瘤和靶向前列腺特异性膜抗原的前列腺癌的成像与治疗,并阐述了患者选择和疗效评估方法。

要点

  • 神经内分泌肿瘤诊疗一体化利用生长抑素受体高表达进行成像与治疗。
  • 前列腺癌诊疗一体化靶向前列腺特异性膜抗原进行成像与治疗。
  • 放射性配体闪烁显像和/或PET用于患者选择和疗效评估。

局限性

  • 本文为叙述性综述,未提供系统检索策略和纳入文献的详细信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Combination of radioligand imaging and therapy, so called radiotheranostics, is a novel tool of precision oncology with proven clinical value. In-depth knowledge of functional imaging nuances is critically needed for precise prognostication and guidance of management. Here, we review theranostic applications with up to Phase III type evidence for outcome improvement: Imaging and therapy of neuroendocrine neoplasms (NEN) exploiting high levels of somatostatin receptor (SSTR) expression and radiotheranostics of prostate cancer targeting the prostate specific membrane antigen (PSMA). This narrative review focusses on these two applications and elucidates patient selection and response assessment by radioligand scintigraphy and/or positron emission tomography. Furthermore, we provide a brief outlook on future applications for novel targets outside of NEN and prostate cancer.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Ferdinandus J, Fendler WP, Morigi JJ, et al. Theranostics in oncology: What radiologists want to know. Eur J Radiol. 2021. PMID: 34391057. doi:10.1016/j.ejrad.2021.109875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。